Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNASDAQ:ATRANASDAQ:GLSINASDAQ:LYEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$6.75-4.3%$9.26$5.51▼$11.99$138.32MN/A51,661 shs96,960 shsATRAAtara Biotherapeutics$8.06+2.3%$7.57$5.01▼$18.71$46.98M0.19123,167 shs29,533 shsGLSIGreenwich LifeSciences$9.05+3.3%$9.58$8.06▼$18.15$117.11M1.6946,178 shs45,034 shsLYELLyell Immunopharma$9.59+6.7%$9.11$7.65▼$43.40$133.12M-0.2669,516 shs91,111 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-4.26%-13.13%-34.66%-15.63%+674,999,900.00%ATRAAtara Biotherapeutics+2.28%+3.33%+12.89%+21.75%-2.72%GLSIGreenwich LifeSciences+3.31%+0.22%-7.75%-14.86%-41.61%LYELLyell Immunopharma+6.67%-1.13%+14.69%-14.04%-77.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate Therapeutics1.37 of 5 stars3.50.00.00.00.61.70.0ATRAAtara Biotherapeutics4.0383 of 5 stars3.33.00.04.70.62.50.6GLSIGreenwich LifeSciences1.5354 of 5 stars3.51.00.00.00.03.30.0LYELLyell Immunopharma3.4595 of 5 stars2.83.00.00.02.95.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.50203.70% UpsideATRAAtara Biotherapeutics 2.57Moderate Buy$17.75120.22% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00330.94% UpsideLYELLyell Immunopharma 1.50Reduce$15.0056.41% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, ACTU, LYEL, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$10.006/3/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.004/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.01 per shareN/AATRAAtara Biotherapeutics$128.94M0.37N/AN/A($16.89) per share-0.48GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/ALYELLyell Immunopharma$65K2,184.75N/AN/A$26.21 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$27.28MN/A0.00∞N/AN/AN/A-339.73%N/AATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)GLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$25.00N/AN/AN/A-514,649.22%-73.66%-60.99%8/6/2025 (Estimated)Latest ATRA, ACTU, LYEL, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/13/2025Q1 2025LYELLyell Immunopharma-$3.80-$3.60+$0.20-$0.18N/A$0.01 million4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A0.460.46ATRAAtara BiotherapeuticsN/A0.570.57GLSIGreenwich LifeSciencesN/A1.911.91LYELLyell ImmunopharmaN/A7.497.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AATRAAtara Biotherapeutics70.90%GLSIGreenwich LifeSciences4.16%LYELLyell Immunopharma66.05%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%ATRAAtara Biotherapeutics4.00%GLSIGreenwich LifeSciences51.67%LYELLyell Immunopharma22.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.62 million6.02 millionN/AATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableLYELLyell Immunopharma27014.81 million11.51 millionOptionableATRA, ACTU, LYEL, and GLSI HeadlinesRecent News About These CompaniesLyell Immunopharma (NASDAQ:LYEL) Price Target Raised to $10.00 at HC WainwrightJune 25 at 2:12 AM | americanbankingnews.comLyell Immunopharma (NASDAQ:LYEL) Stock Price Expected to Rise, HC Wainwright Analyst SaysJune 24 at 8:18 AM | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Trading 3.5% Higher - Here's What HappenedJune 24 at 2:45 AM | americanbankingnews.comLyell Immunopharma (NASDAQ:LYEL) Trading 3.5% Higher - What's Next?June 24 at 2:41 AM | marketbeat.comLyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" SeriesJune 23 at 10:57 PM | tmcnet.comLyell Immunopharma to Discuss Clinical Data on LYL314 at H.C. Wainwright's "HCW@Home" SeriesJune 23 at 5:18 PM | quiverquant.comLyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” SeriesJune 23 at 5:00 PM | globenewswire.comLyell Immunopharma Releases Data From Phase I/II Trial of CD19/20 Dual Targeting CAR T-Cell TherapyJune 20, 2025 | precisionmedicineonline.comLyell reports new clinical data from trial of large B-cell lymphoma therapyJune 18, 2025 | finance.yahoo.comLyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell LymphomaJune 17, 2025 | globenewswire.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Drops By 94.5%June 11, 2025 | marketbeat.comLyell Immunopharma Taps Shook as Chief Medical OfficerJune 11, 2025 | marketwatch.comLyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive AppointmentsJune 9, 2025 | globenewswire.comLyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" RatingJune 7, 2025 | marketbeat.comLyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceJune 4, 2025 | globenewswire.comLyell Immunopharma (NASDAQ:LYEL) Shares Up 14.7% - Should You Buy?June 4, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week Low - Here's What HappenedJune 2, 2025 | marketbeat.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Expands By 71.6%June 1, 2025 | marketbeat.comLyell Immunopharma trading halted, news pendingMay 31, 2025 | msn.comLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 17, 2025 | finanznachrichten.deLyell Immunopharma Advances CAR T-Cell Therapy PipelineMay 14, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookToyota Supercharges Joby: $250M Capital Infusion Ignites Stock By Jeffrey Neal Johnson | May 28, 2025View Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Micron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawBy Leo Miller | June 4, 2025View Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawTesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBy Sam Quirke | June 11, 2025View Tesla Stock: Why These 2 Downgrades Are Actually a Buy SignalATRA, ACTU, LYEL, and GLSI Company DescriptionsActuate Therapeutics NASDAQ:ACTU$6.75 -0.30 (-4.26%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$6.72 -0.03 (-0.37%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Atara Biotherapeutics NASDAQ:ATRA$8.06 +0.18 (+2.28%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$8.06 0.00 (0.00%) As of 06/24/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Greenwich LifeSciences NASDAQ:GLSI$9.05 +0.29 (+3.31%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$9.06 +0.01 (+0.07%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Lyell Immunopharma NASDAQ:LYEL$9.59 +0.60 (+6.67%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$9.72 +0.13 (+1.30%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Insiders Chase Income and Stability in American Tower—Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
